|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 850.60 INR | -0.21% |
|
-2.78% | +13.19% |
| 05-28 | Supriya Lifescience Limited, Q4 2026 Earnings Call, May 28, 2026 | |
| 05-27 | Supriya Lifescience Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 | CI |
| Market Cap | 68.46B 710M 621M 574M 527M 997M 1.01B 6.85B 2.69B 33.43B 2.67B 2.61B 115B | P/E 2026 |
21.6x | P/E 2027 * | 28.4x |
|---|---|---|---|---|---|
| Enterprise Value | 68.46B 710M 621M 574M 527M 997M 1.01B 6.85B 2.69B 33.43B 2.67B 2.61B 115B | EV / Sales 2026 |
5.46x | EV / Sales 2027 * | 6.89x |
| Free-Float |
28.72% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Supriya Lifescience Limited
| 1 day | -0.21% | ||
| 1 week | -2.78% | ||
| Current month | -16.45% | ||
| 1 month | -10.17% | ||
| 3 months | +35.38% | ||
| 6 months | +15.42% | ||
| Current year | +13.19% |
| 1 week | 838 |  | 875 |
| 1 month | 835.5 | | 1,043.2 |
| Current year | 545.5 | | 1,085 |
| 1 year | 545.5 | | 1,085 |
| 3 years | 233.3 | | 1,085 |
| 5 years | 170.15 | | 1,085 |
| 10 years | 170.15 | | 1,085 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 34 | 2024-07-31 | |
| Chief Executive Officer | 36 | 2024-07-31 | |
| Director of Finance/CFO | - | 2023-01-22 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 73 | 2025-01-23 | |
| Director/Board Member | 67 | 2021-03-24 | |
| Chairman | 70 | 2008-03-25 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.21% | -2.78% | +18.00% | +259.81% | 710M | |
| +1.08% | -3.93% | +48.03% | +160.13% | 1,043B | |
| +1.19% | -3.52% | +51.70% | +56.36% | 602B | |
| +4.21% | +1.79% | +33.48% | +87.04% | 449B | |
| +1.18% | -0.62% | +30.16% | +24.72% | 327B | |
| +1.23% | +0.05% | +33.21% | +46.42% | 279B | |
| -0.50% | -2.46% | +21.39% | +22.73% | 264B | |
| +3.70% | +2.19% | +24.27% | +63.38% | 201B | |
| +3.49% | +1.08% | +24.08% | +76.58% | 169B | |
| +1.29% | +3.67% | +2.15% | -30.78% | 143B | |
| Average | +0.93% | -0.66% | +28.65% | +76.64% | 347.78B | |
| Weighted average by Cap. | +1.00% | -1.82% | +37.46% | +82.95% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 8.4B 87.17M 76.2M 70.47M 64.66M 122M 125M 840M 330M 4.1B 327M 320M 14.16B | 9.94B 103M 90.12M 83.35M 76.48M 145M 147M 994M 390M 4.85B 387M 379M 16.75B |
| Net income | 2B 20.77M 18.15M 16.79M 15.4M 29.15M 29.66M 200M 78.64M 977M 77.98M 76.27M 3.37B | 2.41B 25M 21.85M 20.21M 18.54M 35.1M 35.71M 241M 94.68M 1.18B 93.89M 91.82M 4.06B |
| Net Debt | - | - |
Employees
515
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-16 | ₹850.60 | -0.21% | 123,732 |
| 26-07-15 | ₹852.40 | -2.10% | 116,682 |
| 26-07-14 | ₹870.70 | +3.04% | 344,442 |
| 26-07-13 | ₹845.00 | -1.12% | 218,343 |
| 26-07-10 | ₹854.60 | -2.32% | 238,089 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUPRIYA Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
